In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Abstract

Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin were measured for 180 B. cepacia complex and 101 S. maltophilia CF isolates and were 100 μg/ml for both species. New inhalation devices that deliver high tobramycin levels to the lung may be able to exceed these MICs.

• Authors: Anina Ratjen, Yvonne Yau, Jillian Wettlaufer, Larissa Matukas, James E A Zlosnik, David P Speert, John J LiPuma, Elizabeth Tullis, Valerie Waters
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 59 Issue 1 Pg. 711-3 (Jan 2015) ISSN: 1098-6596 [Electronic] United States
• PMID: 25348526 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Chemical References

• Anti-Bacterial Agents
• Tobramycin

Topics

• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Biofilms (drug effects)
• Burkholderia Infections (drug therapy, etiology, microbiology)
• Burkholderia cepacia complex (drug effects)
• Cystic Fibrosis (complications, microbiology)
• Gram-Negative Bacterial Infections (drug therapy, etiology, microbiology)
• Humans
• Microbial Sensitivity Tests
• Stenotrophomonas maltophilia (drug effects)
• Tobramycin (pharmacology, therapeutic use)